Cystadane Trial Shows Reduced Biomarkers and Functional Gains in Aspartylglucosaminuria
An open-label phase Ib/II clinical trial demonstrated that oral Cystadane significantly reduced urinary glycoasparagines and improved functional measures in pediatric ...

